> Detailanzeige

Nagabushan, Sumanth; Lau, Loretta M. S.; Barahona, Paulette; Wong, Marie; Sherstyuk, Alexandra; Marshall, Glenn M.; Tyrrell, Vanessa; Wegner, Eva A.; Ekert, Paul G.; Cowley, Mark J.; Mayoh, Chelsea; Trahair, Toby N.; Crowe, Philip; Anazodo, Antoinette; Ziegler, David S.

Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor
  • Beteiligte: Nagabushan, Sumanth; Lau, Loretta M. S.; Barahona, Paulette; Wong, Marie; Sherstyuk, Alexandra; Marshall, Glenn M.; Tyrrell, Vanessa; Wegner, Eva A.; Ekert, Paul G.; Cowley, Mark J.; Mayoh, Chelsea; Trahair, Toby N.; Crowe, Philip; Anazodo, Antoinette; Ziegler, David S.
  • Erschienen: Springer Science and Business Media LLC, 2021
  • Erschienen in: npj Precision Oncology, 5 (2021) 1
  • Sprache: Englisch
  • DOI: 10.1038/s41698-021-00145-8
  • ISSN: 2397-768X
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: AbstractThe prognosis of recurrent malignant peripheral nerve sheath tumors (MPNST) is dismal, with surgical resection being the only definitive salvage therapy. Treatment with chemoradiation approaches has not significantly improved patient outcomes. Similarly, trials of therapies targeting MPNST genomic drivers have thus far been unsuccessful. Improved understanding of the molecular pathogenesis of MPNST indicates frequent activation of the mitogen-activated protein kinase (MAPK) cell signaling pathway. MEK inhibitors have shown activity in preclinical studies; however, their clinical efficacy has not been reported to date. We describe here a case of sustained complete response to MEK inhibition in an adolescent patient with a recurrent metastatic MPNST with multiple alterations in the MAPK pathway, guided by a precision oncology approach.
  • Zugangsstatus: Freier Zugang